261 related articles for article (PubMed ID: 23561929)
1. Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis.
Ishikawa S; Shimizu M; Ueno K; Sugimoto N; Yachie A
Cytokine; 2013 May; 62(2):272-7. PubMed ID: 23561929
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-33 as a marker of disease activity in rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
Ishikawa S; Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Yachie A
Mod Rheumatol; 2017 Jul; 27(4):609-613. PubMed ID: 27785924
[TBL] [Abstract][Full Text] [Related]
3. Compensated inflammation in systemic juvenile idiopathic arthritis: role of alternatively activated macrophages.
Shimizu M; Yachie A
Cytokine; 2012 Oct; 60(1):226-32. PubMed ID: 22682876
[TBL] [Abstract][Full Text] [Related]
4. Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis.
Sakumura N; Shimizu M; Mizuta M; Inoue N; Nakagishi Y; Yachie A
Cytokine; 2018 Oct; 110():459-465. PubMed ID: 29801971
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis: associated with disease activity and vascular endothelial growth factor.
Li XL; Lin TT; Qi CY; Yuan L; Xia LP; Shen H; Lu J
J Investig Med; 2013 Jun; 61(5):848-51. PubMed ID: 23552178
[TBL] [Abstract][Full Text] [Related]
6. Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's Syndrome.
Zhao L; Yao L; Yuan L; Xia L; Shen H; Lu J
Cytokine; 2013 Oct; 64(1):22-4. PubMed ID: 23910012
[TBL] [Abstract][Full Text] [Related]
7. The levels of soluble ST2 in sera and bullous fluid from patients with bullous pemphigoid.
Wakatabi K; Komine M; Meephansan J; Matsuyama Y; Tsuda H; Tominaga S; Ohtsuki M
Eur J Dermatol; 2012; 22(3):333-6. PubMed ID: 22494834
[TBL] [Abstract][Full Text] [Related]
8. Serum Leucine-Rich
Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Yachie A
J Immunol Res; 2019; 2019():3140204. PubMed ID: 30863782
[TBL] [Abstract][Full Text] [Related]
9. Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis.
Lin CY; Pfluger CM; Henderson RD; McCombe PA
J Neuroimmunol; 2012 Aug; 249(1-2):93-5. PubMed ID: 22633272
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis.
Mizuta M; Shimizu M; Inoue N; Ikawa Y; Nakagishi Y; Yasuoka R; Iwata N; Yachie A
Rheumatology (Oxford); 2021 May; 60(5):2421-2426. PubMed ID: 33200207
[TBL] [Abstract][Full Text] [Related]
11. Soluble ST2 and IL-33: Potential markers of endometriosis in the Tunisian population.
Mbarik M; Kaabachi W; Henidi B; Sassi FH; Hamzaoui K
Immunol Lett; 2015 Jul; 166(1):1-5. PubMed ID: 25977120
[TBL] [Abstract][Full Text] [Related]
12. High plasma levels of soluble ST2 but not its ligand IL-33 is associated with severe forms of pediatric dengue.
Guerrero CD; Arrieta AF; Ramirez ND; Rodríguez LS; Vega R; Bosch I; Rodríguez JA; Narváez CF; Salgado DM
Cytokine; 2013 Mar; 61(3):766-71. PubMed ID: 23357301
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of IL-33 and its receptor ST2 are elevated in patients with ankylosing spondylitis.
Li GX; Wang S; Duan ZH; Zeng Z; Pan FM
Scand J Rheumatol; 2013; 42(3):226-31. PubMed ID: 23409750
[TBL] [Abstract][Full Text] [Related]
14. Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet's disease.
Kim DJ; Baek SY; Park MK; Park KS; Lee JH; Park SH; Kim HY; Kwok SK
J Korean Med Sci; 2013 Aug; 28(8):1145-53. PubMed ID: 23960440
[TBL] [Abstract][Full Text] [Related]
15. Levels of soluble ST2 in serum associated with severity of dengue due to tumour necrosis factor alpha stimulation.
Houghton-Triviño N; Salgado DM; Rodríguez JA; Bosch I; Castellanos JE
J Gen Virol; 2010 Mar; 91(Pt 3):697-706. PubMed ID: 19889931
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus.
Mok MY; Huang FP; Ip WK; Lo Y; Wong FY; Chan EY; Lam KF; Xu D
Rheumatology (Oxford); 2010 Mar; 49(3):520-7. PubMed ID: 20026564
[TBL] [Abstract][Full Text] [Related]
17. The Interleukin 33/ST2 axis in patients with primary Sjögren syndrome: expression in serum and salivary glands, and the clinical association.
Jung SM; Lee J; Baek SY; Lee JH; Lee J; Park KS; Park SH; Kim HY; Kwok SK
J Rheumatol; 2015 Feb; 42(2):264-71. PubMed ID: 25512474
[TBL] [Abstract][Full Text] [Related]
18. The profile of polyunsaturated fatty acids in juvenile idiopathic arthritis and association with disease activity.
Gorczyca D; Postępski J; Czajkowska A; Paściak M; Prescha A; Olesińska E; Gruenpeter A; Lachór-Motyka I; Szponar B
Clin Rheumatol; 2017 Jun; 36(6):1269-1279. PubMed ID: 28247163
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-33/ST2 signaling contributes to the severity of hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli.
Yamada S; Shimizu M; Kuroda M; Inoue N; Sugimoto N; Yachie A
Clin Exp Nephrol; 2019 Apr; 23(4):544-550. PubMed ID: 30467800
[TBL] [Abstract][Full Text] [Related]
20. Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction.
Zhang K; Zhang XC; Mi YH; Liu J
Chin Med J (Engl); 2013; 126(19):3628-31. PubMed ID: 24112154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
